Ureaplasmas in acute and persistent urethritis: clinical implications

解脲支原体在急性和持续性尿道炎中的临床意义

基本信息

  • 批准号:
    8068051
  • 负责人:
  • 金额:
    $ 13.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-10 至 2012-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Project Summary. Nongonococcal urethritis (NGU) is the most common sexually transmitted disease syndrome seen in men in the United States, yet up to 50% of cases have no defined etiology. Even less is known about the etiology of persistent or recurrent urethritis, which is also frequent. Ureaplasma urealyticum may be responsible for some of these idiopathic cases, but evidence regarding pathogencity of the organism and the degree to which it is associated with acute or persistent NGU is conflicting. Similar to the serovars of Chlamydia trachomatis, Ureaplasma serovars may exhibit varying degrees of pathogenicity, and recent phylogenetic analyses have demonstrated that the two major Ureaplasma biovar groupings are actually distinct species. U. parvum has been designated biovar 1, while the name U. urealyticum was retained for biovar 2. Limited data suggest that U. urealyticum (biovar 2), but not U. parvum is associated with NGU, but further studies are required to confirm this observation, as well as to assess the differential response of these two species to common antibiotic treatment regimens for NGU, and to identify the role of this organism in persistent or recurrent NGU. To address these questions, we will conduct a series of studies in conjunction with an ongoing randomized treatment trial of another genital Mycoplasma, M. genitalium. Specifically, we will 1) Assess the association of U. urealyticum (biovar 2) and U. parvum with acute NGU; 2) Determine, in our ongoing randomized double-blind trial, the relative efficacy of azithromycin and doxycycline in eradicating U. urealyticum (biovar 2) and U. parvum infection among men with NGU, and assess the relationship of the MIC of the drug used to persistence of U. urealyticum (biovar 2) and U. parvum; and 3) Evaluate the association of persistent or recurrent NGU with U. urealyticum (biovar 2) and U. parvum. Relevance. NGU is the subject of over 200,000 physician office visits per year (CDC, 2001), and represents a significant public health problem. The results of this study may lead to the identification of an additional cause of this syndrome, provide guidance on treatment decisions, and shed light on the etiology of persistent and recurrent cases.
描述(由申请人提供):项目摘要。非淋菌性尿道炎(NGU)是美国男性最常见的性传播疾病综合征,但高达50%的病例没有明确的病因。持续性或复发性尿道炎的病因学更是知之甚少,这也是常见的。解脲脲原体可能是这些特发性病例的原因,但关于该病原体的致病性及其与急性或持续性NGU相关程度的证据是相互矛盾的。与沙眼衣原体的血清型相似,脲原体血清型可能表现出不同程度的致病性,最近的系统发育分析表明,两个主要的脲原体生物型分组实际上是不同的物种。联合parvum已被指定为生物变型1,而U.生物变型2保留溶脲菌。有限的数据表明,美国。溶脲脲原体(biovar 2),而非溶脲脲原体(U.小孢子虫与NGU有关,但需要进一步的研究来证实这一观察结果,以及评估这两个物种对NGU常用抗生素治疗方案的不同反应,并确定这种生物体在持续性或复发性NGU中的作用。为了解决这些问题,我们将进行一系列的研究,并结合正在进行的另一种生殖道支原体M的随机治疗试验。生殖器具体来说,我们将1)评估美国的协会。溶脲脲原体(biovar 2)和溶脲脲原体(U.急性非淋菌性尿道炎; 2)在我们正在进行的随机双盲试验中,确定阿奇霉素和多西环素根除U的相对疗效。溶脲脲原体(biovar 2)和溶脲脲原体(U.目的:探讨非淋菌性尿道炎(NGU)男性患者微小支原体感染情况,并评估药物MIC与U. p.持续性的关系。溶脲脲原体(biovar 2)和溶脲脲原体(U.评估持续性或复发性NGU与U的关系。溶脲脲原体(biovar 2)和溶脲脲原体(U.小的本案无关NGU是每年超过200,000次医生办公室访问的主题(CDC,2001),并且代表了一个重要的公共卫生问题。这项研究的结果可能导致识别这种综合征的另一个原因,提供治疗决策的指导,并阐明持续和复发病例的病因。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa E Manhart其他文献

Lisa E Manhart的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lisa E Manhart', 18)}}的其他基金

Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
美国沙眼衣原体和生殖支原体的累积负担:对筛查指南和抗菌素耐药性的影响
  • 批准号:
    10397644
  • 财政年份:
    2021
  • 资助金额:
    $ 13.05万
  • 项目类别:
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
美国沙眼衣原体和生殖支原体的累积负担:对筛查指南和抗菌素耐药性的影响
  • 批准号:
    10616677
  • 财政年份:
    2021
  • 资助金额:
    $ 13.05万
  • 项目类别:
Mycoplasma genitalium Susceptibility and Treatment
生殖支原体的易感性和治疗
  • 批准号:
    7962199
  • 财政年份:
    2009
  • 资助金额:
    $ 13.05万
  • 项目类别:
Integrating Depression Screening into HIV-care in Southern India.
将抑郁症筛查纳入印度南部的艾滋病毒护理。
  • 批准号:
    7944025
  • 财政年份:
    2009
  • 资助金额:
    $ 13.05万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7573466
  • 财政年份:
    2007
  • 资助金额:
    $ 13.05万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7268263
  • 财政年份:
    2007
  • 资助金额:
    $ 13.05万
  • 项目类别:
Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
  • 批准号:
    7365146
  • 财政年份:
    2007
  • 资助金额:
    $ 13.05万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7076945
  • 财政年份:
    2004
  • 资助金额:
    $ 13.05万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7470557
  • 财政年份:
    2004
  • 资助金额:
    $ 13.05万
  • 项目类别:
Principles of STD and HIV Research
性病和艾滋病毒研究原理
  • 批准号:
    7262564
  • 财政年份:
    2004
  • 资助金额:
    $ 13.05万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.05万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了